References
- Castano L., Eisenbarth G. S. Type i diabetes: a chronic autoimmune disease of the human, mouserat. Ann. Rev. Immunol. 1990; 8: 647–679
- Riley W. J., MacLaren N. K., Krischer J., Spillar R. P., Silverstein J. H., Schatz D. A., Shwartz S., Malone J., Shah S., Vadheim C., Rotter J. I. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N. Engl. J. Med. 1990; 323: 1167–1172
- Vardi P., Crisa' L., Jackson R. A, Herskowitz R. D, Wolfsdorf J. I, Einhorm D., Linarelli D., Dolinar R., Wentworth S., Brink S. J, Starkman H., Soeldner J. S., Eisenbarth G. S. Predictive value of intravenous glucose tolerance test insulin secretion less or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991; 34: 39–102
- Palmer J. P., Asplin C. M, Clemons P., Lyen K., Tatpati O., Raghu P. K., Paquette T. L. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337–1339
- Harrison L. C., Honeyman M. C, DeAizpura H. J, Schmidli R. S, Colman P. G, Tait B. D., Cram D. S. Inverse relation between humoralcellular immunity to glutamic acid decarboxylase in subjects at risk of insulindependent diabetes. Lancet 1993; 341: 1365–1369
- Dotta F., Gianani R., Previti M., Lenti L., Dionisi S., D'Erme M., Eisenbarth G. S., Di Mario U. Autoimmunity to the GM2–1 islet ganglioside beforeat the onset of the type 1 diabetes. Diabetes 1996; 45: 1193–1196
- Bonifacio E., Bingley P. J, Shattock M., Dean B. M, Dunger D., Gale E. A.M., , Bottazzo G. F, et al. Qnantification of islet-cell antibodiesprediction of insulindependent diabetes. Lancet 1990; 335: 147–149
- Rabin D. U., Pleasic S. M, Shapiro J. A, Yoo-Waren H., Oles I., Hicks J. M, Goldstein D. E., Rea P. M.M. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J. Immunol. 1994; 152: 3183–3188
- Castano L., Russo E., Zhou L., Lipes M. A., , Eisenbarth G. S, et al. Identificationcloning of a granule autoantigen (carboxypeptidase H) associated with type 1 diabetes. J. Clin. Endocrinol. Metab. 1991; 73: 1197–1201
- Shah S., Malone J., Simpson N. E. A randomized trial of intensive insulin therapy in newly diagnosed insulin dependent diabetes mellitus. N. Engl. J. Med. 1989; 320: 540–544
- Hramiak I., Mahon J., Finegood D., Dupre J. Effect of short course of high dose insulin treatment in insulin dependent diabetes mellitus. Clin. Invest. Med. 1991; 14: 28A
- Chase H. P., Butler-Simon N., Garg S., McDuffie M., Hoops S. L., O'Brien D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 444–446
- Elliott R., Chase H. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34: 362–365
- Godfredson G. F., Busehard K., Frandsen E. K. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes prone animals. Diabetologia 1985; 28: 933–935
- Atkinson M. A., MacLaren N. K., Lucchetta R. Insulitisdiabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39: 933–937
- Bowman M. A., Campbell L., Darrow B. L, Ellis T. M, Suresh A., Atkinson M. A. Immunologicalmetabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 1996; 45: 205–208
- Keller R. J., Eisenbarth G. S., Jackson R. A. Insulin prophylaxis individuals at high risk of type I diabetes. Lancet 1993; 341: 927–928
- Eisenbarth G. S., Verge C. F, Allen H., Rewers M. J. The design of trials for prevention of IDDM. Diabetes 1993; 42: 941–947
- Like A. A., Rossini A. A. Streptozotocin-induced pancreatic insulitis. New model of diabetes mellitus. Science (Wash. DC) 1976; 193: 415–417
- Anastasi E., Tiberti C., Sensi M., Ponte E., Filippetti R., Dotta F., Vecci E., Fiori M. G., Di Mario U. Pancreatic gangliosides delay the onset of insulitishyperglycaemia in the low-dose streptozotocin mouse model. Scand. J. Immunol. 1993; 37: 308–313
- Sai P., Elmansour A., Audrain M., Charbonel B., Bardet S. Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow up study in type 1 (insulin-dependent) diabetic patientsin first degree relatives. Diabetologia 1993; 36: 778–784
- Svennerholm L., Fredman P. A procedure for quantitative isolation of brain gangliosides. Biochem. Biophys. Acta 1980; 617: 97–109
- Williams M. A., McCluer R. H. The use of Sep-Pak C18 cartridges during the isolation of gangliosides. J. Neurochem. 1980; 35: 266–269
- Svennerholm L. Chromatographic separation of human brain gangliosides. J. Neurochem. 1963; 10: 613–623
- Schnedl W. J, Ferher S., Johnson J. H., Newgard C. B. STZ transportcytotoxicity. Diabetes 1994; 43: 1326–1333
- Dotta F., Previti M., Nerman-Arbez M., Dionisi S., Cucinotta D., Lenti L., Di Mario U., Halban P. A. The GM2–1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granulesis not β-cell specific. Endorinology 1998; 189: 316–319
- Bjork E., Kampe O., Grawe J., Halberg A., Norheim I., Kalsson F. A. Modulation of beta-cell activityits influence on islet cell antibody (ICA)islet cell surface antibody (ICSA) reactivity. Autoimmunity 1993; 16: 181–188
- Aaen K., Rygaard J., Jofensen K., Petersen H., Brogren C. H, Horn T., Bushard K. Dependence of antigen expression on functional state of beta-cells. Diabetes 1990; 39: 697–701